Bicycle Therapeutics (BCYC) Expected to Announce Quarterly Earnings on Tuesday

Bicycle Therapeutics (NASDAQ:BCYC) is projected to announce its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $5.47 million for the quarter.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $12.55 on Friday. Bicycle Therapeutics has a 1 year low of $11.14 and a 1 year high of $28.67. The company has a market capitalization of $866.58 million, a price-to-earnings ratio of -3.81 and a beta of 0.93. The business has a 50-day moving average of $14.31 and a 200-day moving average of $20.13.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on BCYC shares. Stephens restated an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th. B. Riley lowered their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, JMP Securities lowered their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.25.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the transaction, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at $482,190. The trade was a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker bought 500,000 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were bought at an average cost of $15.34 per share, for a total transaction of $7,670,000.00. Following the transaction, the director now owns 9,995,274 shares of the company’s stock, valued at $153,327,503.16. The trade was a 5.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.